Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOBER: 12 Weeks Adjuvant Docetaxel Plus Trastuzumab in Early HER2+ Breast Cancer
NCT03367676Phase 2Terminated
- Sponsor
- Ruijin Hospital
- Start
- Dec 2017
- Primary completion
- Jul 2024
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab, docetaxel in breast cancer, sponsored by Ruijin Hospital. Started Dec 2017; status: terminated.
02
Drugs
trastuzumabdocetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03367676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03367676.